<?xml version="1.0" encoding="UTF-8"?>
<ack>
 <title>Acknowledgements</title>
 <p>A.L.P. and S.K. are funded by MSWA, The Michael J. Fox Foundation, Shake It Up Australia and Perron Institute for Neurological and Translational Science. This work was supported by resources provided by the Pawsey Supercomputing Centre with funding from the Australian Government and the Government of Western Australia. Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (
  <ext-link ext-link-type="uri" xlink:href="http://www.ppmi-info.org/data" xmlns:xlink="http://www.w3.org/1999/xlink">www.ppmi-info.org/data</ext-link>). For up-to-date information on the study, visit 
  <ext-link ext-link-type="uri" xlink:href="http://www.ppmi-info.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.ppmi-info.org</ext-link>. PPMI—a public-private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbvie, Allergan, Amathus therapeutics, Avid Radiopharmaceuticals, Biogen Idec, Biolegend, Briston-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech, GlaxoSmithKline, janssen neuroscience, Lilly, Lundbeck, Merck, Meso Scale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily and Voyager Therapeutics. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.
 </p>
</ack>
